Pfizer Australia Media Affairs

Maida Talhami
Manager, Media Communications
Tel: (02) 9850 3578 or 0488 274 093

media@pfizer.com.au

Latest news

Pfizer Australia Confirms Contraceptive Efficacy

Wednesday June 11, 2003

Pfizer Australia strongly rejects suggestions that its injectable, doctor-administered contraceptive products, Depo-Provera and Depo-Ralovera , are unreliable, as suggested in a Melbourne newspaper today.

The report was sourced from a routine bulletin issued a week ago by ADRAC, the body that monitors adverse drug reactions in Australia.

Today’s article is misleading because it linked Depo-Provera and Depo-Ralovera, to an unrelated implant product from another company, the use of which has been associated with bleeding.

As acknowledged by ADRAC, Depo-Provera is one of the most effective forms of contraception available. Like all treatments, there is nevertheless a small risk of pregnancy, especially if the drug is not administered by doctors according to guidelines.

We strongly support the correct use of Depo Provera, as per the instructions attached to the product.

As pointed out in the media today by Family Planning Victoria, both products are far more effective in preventing pregnancy than tubal ligation.

Depo-Provera and Depo-Ralovera (medroxyprogesterone acetate aqueous suspension injection) are indicated for contraceptive purposes as well as for the treatment of carcinoma and endometriosis. They are injectible medications, with the dosage and frequency of use depending upon the reason for prescribing. Depo Provera and Depo Ralavera are PBS listed for their approved indications. The full text of the Consumer Medical Information for Depo Provera and Depo Ralavera can be viewed here.